Verona Pharma (VRNA) News Today → Warren Buffett's 'mystery stock' (From Stansberry Research) (Ad) Free VRNA Stock Alerts $12.83 -0.17 (-1.31%) (As of 01:51 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 4:03 AM | americanbankingnews.comResearch Analysts Offer Predictions for Verona Pharma plc's FY2024 Earnings (NASDAQ:VRNA)May 16, 2024 | marketbeat.comVerona Pharma plc Expected to Post FY2024 Earnings of ($1.36) Per Share (NASDAQ:VRNA)Verona Pharma plc (NASDAQ:VRNA - Free Report) - HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for Verona Pharma in a research report issued to clients and investors on Monday, May 13th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings perMay 15, 2024 | marketbeat.comNicholas Investment Partners LP Trims Position in Verona Pharma plc (NASDAQ:VRNA)Nicholas Investment Partners LP lessened its stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 85.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 169,126 shares of the company's stock after selling 993,863 sharMay 15, 2024 | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Price Target Cut to $30.00May 14, 2024 | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Stock Price Down 5.8% on Analyst DowngradeMay 13, 2024 | markets.businessinsider.comStrategic Financing Secures Verona Pharma’s Future Beyond 2026, Ensuring Buy RatingMay 13, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Shares Down 5.8% on Analyst DowngradeVerona Pharma (NASDAQ:VRNA) Shares Down 5.8% on Analyst DowngradeMay 10, 2024 | finance.yahoo.comVerona Pharma PLC Reports Q1 2024 Earnings: A Detailed Financial and Strategic OverviewMay 10, 2024 | finance.yahoo.comVerona Pharma plc (NASDAQ:VRNA) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finanznachrichten.deVerona Pharma plc: Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | finance.yahoo.comVerona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERSMay 9, 2024 | globenewswire.comVerona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | globenewswire.comVerona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERSMay 6, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Shares Down 4.3% on Insider SellingVerona Pharma (NASDAQ:VRNA) Stock Price Down 4.3% on Insider SellingMay 5, 2024 | insidertrades.comKathleen A. Rickard Sells 36,248 Shares of Verona Pharma plc (NASDAQ:VRNA) StockMay 3, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Insider Kathleen A. Rickard Sells 36,248 SharesVerona Pharma plc (NASDAQ:VRNA - Get Free Report) insider Kathleen A. Rickard sold 36,248 shares of the firm's stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $1.96, for a total transaction of $71,046.08. Following the sale, the insider now owns 2,621,552 shares of the company's stock, valued at $5,138,241.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.May 2, 2024 | globenewswire.comVerona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024April 27, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) is Vivo Capital LLC's 6th Largest PositionVivo Capital LLC lowered its position in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 15.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,610,177 shares of the company's stock after sellinApril 25, 2024 | marketbeat.comJennison Associates LLC Acquires 142,819 Shares of Verona Pharma plc (NASDAQ:VRNA)Jennison Associates LLC grew its holdings in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 9.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,585,385 shares of the company's stock afterApril 25, 2024 | investing.comVerona Pharma shares target raised on COPD launch outlookApril 25, 2024 | globenewswire.comVerona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate UpdateApril 16, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Stock Price Up 3.7% on Analyst UpgradeVerona Pharma (NASDAQ:VRNA) Trading Up 3.7% on Analyst UpgradeApril 16, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) PT Raised to $36.00 at Piper SandlerPiper Sandler increased their target price on shares of Verona Pharma from $31.00 to $36.00 and gave the stock an "overweight" rating in a report on Tuesday.April 4, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Shares Up 4.9%Verona Pharma (NASDAQ:VRNA) Trading 4.9% HigherMarch 28, 2024 | marketbeat.comAmerican Century Companies Inc. Purchases Shares of 280,126 Verona Pharma plc (NASDAQ:VRNA)American Century Companies Inc. purchased a new stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 280,126 shares of the company's stock, valued at approximateMarch 19, 2024 | marketbeat.comWellington Management Group LLP Acquires 164,268 Shares of Verona Pharma plc (NASDAQ:VRNA)Wellington Management Group LLP lifted its holdings in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 3.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,467,571 shares of theMarch 16, 2024 | finance.yahoo.comVRNA Apr 2024 17.500 callMarch 16, 2024 | finance.yahoo.comVRNA Apr 2024 15.000 callMarch 14, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Trading Down 7.6%Verona Pharma (NASDAQ:VRNA) Trading Down 7.6%March 10, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Buys 208,100 Shares of Verona Pharma plc (NASDAQ:VRNA)Adage Capital Partners GP L.L.C. grew its holdings in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 95.1% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 426,931 shares of the company's stock after buying an additionalMarch 7, 2024 | marketbeat.comResearch Analysts Set Expectations for Verona Pharma plc's Q3 2024 Earnings (NASDAQ:VRNA)Verona Pharma plc (NASDAQ:VRNA - Free Report) - Equities researchers at HC Wainwright reduced their Q3 2024 earnings estimates for Verona Pharma in a research report issued on Monday, March 4th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.32) per sharMarch 6, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Forecasted to Post Q4 2025 Earnings of ($0.01) Per ShareVerona Pharma plc (NASDAQ:VRNA - Free Report) - Investment analysts at HC Wainwright issued their Q4 2025 earnings estimates for shares of Verona Pharma in a research note issued to investors on Monday, March 4th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earningsMarch 4, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Stock Rating Reaffirmed by HC WainwrightHC Wainwright restated a "buy" rating and issued a $32.00 target price on shares of Verona Pharma in a research note on Monday.March 4, 2024 | globenewswire.comAndrew Fisher Joins Verona Pharma as General CounselMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed: Verona Pharma’s Promising Future with Ensifentrine and Expanding R&D PipelineMarch 1, 2024 | finance.yahoo.comVerona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Rating Reiterated by WedbushWedbush reiterated an "outperform" rating and issued a $33.00 price objective on shares of Verona Pharma in a research note on Friday.March 1, 2024 | fool.com3 Healthcare Stocks That Have Outperformed Nvidia Since 2022February 29, 2024 | seekingalpha.comVerona Pharma plc 2023 Q4 - Results - Earnings Call PresentationFebruary 29, 2024 | finanznachrichten.deVerona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 29, 2024 | finance.yahoo.comVerona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 29, 2024 | globenewswire.comVerona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 28, 2024 | markets.businessinsider.comVerona Pharma earnings preview: what to expectFebruary 27, 2024 | marketbeat.comAvidity Partners Management LP Sells 124,200 Shares of Verona Pharma plc (NASDAQ:VRNA)Avidity Partners Management LP cut its holdings in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 13.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 830,300 shares of the company's stock after seFebruary 25, 2024 | finance.yahoo.comWhen Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit?February 25, 2024 | wsj.comVerona Pharma PLC ADRFebruary 23, 2024 | marketbeat.comFederated Hermes Inc. Has $40.65 Million Stock Position in Verona Pharma plc (NASDAQ:VRNA)Federated Hermes Inc. lifted its holdings in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 49.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,493,530 shares of the company's stock after buying an additional 822,832February 17, 2024 | finance.yahoo.comVRNA Mar 2024 15.000 putFebruary 17, 2024 | finance.yahoo.comVRNA Jun 2024 30.000 callFebruary 15, 2024 | seekingalpha.comVerona Pharma: A Few Points From The Bull And Bear Case Get Verona Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Does this make you sick? (Ad)The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments. Get your Free Wealth Protection Kit VRNA Media Mentions By Week VRNA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRNA News Sentiment▼0.130.42▲Average Medical News Sentiment VRNA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRNA Articles This Week▼112▲VRNA Articles Average Week Get Verona Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ABCL News MNKD News COLL News MIRM News ELVN News PCRX News SYRE News BLTE News PRTA News GYRE News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRNA) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsThis Could be Your “Big Money” AI MomentInvestorPlaceDigitizing the $11T commodities sector with one tiny stockResource Stock DigestObama’s Forever Term [exposed]Porter & CompanyNew Options need New Trading StrategiesNetpicks Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
